Segments of business and geographic areas - Sales By Segment Of Business (Details) - USD ($)
$ in Millions |
3 Months Ended |
Mar. 29, 2026 |
Mar. 30, 2025 |
| Sales by segment of business |
|
|
| Sales to customers |
$ 24,062
|
$ 21,893
|
| Percent Change (as a percent) |
9.90%
|
|
| U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 13,330
|
12,305
|
| Percent Change (as a percent) |
8.30%
|
|
| International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 10,732
|
9,588
|
| Percent Change (as a percent) |
11.90%
|
|
| Innovative Medicine |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 15,426
|
13,873
|
| Percent Change (as a percent) |
11.20%
|
|
| Innovative Medicine | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 8,871
|
8,092
|
| Percent Change (as a percent) |
9.60%
|
|
| Innovative Medicine | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 6,555
|
5,781
|
| Percent Change (as a percent) |
13.40%
|
|
| Innovative Medicine | Oncology |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 6,973
|
5,678
|
| Percent Change (as a percent) |
22.80%
|
|
| Innovative Medicine | Oncology | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 3,615
|
3,013
|
| Percent Change (as a percent) |
20.00%
|
|
| Innovative Medicine | Oncology | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 3,358
|
2,664
|
| Percent Change (as a percent) |
26.00%
|
|
| Innovative Medicine | Oncology | DARZALEX |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 3,964
|
3,237
|
| Percent Change (as a percent) |
22.50%
|
|
| Innovative Medicine | Oncology | DARZALEX | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 2,208
|
1,829
|
| Percent Change (as a percent) |
20.70%
|
|
| Innovative Medicine | Oncology | DARZALEX | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,756
|
1,409
|
| Percent Change (as a percent) |
24.70%
|
|
| Innovative Medicine | Oncology | CARVYKTI |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 597
|
369
|
| Percent Change (as a percent) |
62.10%
|
|
| Innovative Medicine | Oncology | CARVYKTI | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 433
|
318
|
| Percent Change (as a percent) |
36.20%
|
|
| Innovative Medicine | Oncology | CARVYKTI | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 164
|
51
|
| Innovative Medicine | Oncology | Tecvayli |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 202
|
151
|
| Percent Change (as a percent) |
33.50%
|
|
| Innovative Medicine | Oncology | Tecvayli | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 127
|
105
|
| Percent Change (as a percent) |
20.60%
|
|
| Innovative Medicine | Oncology | Tecvayli | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 74
|
46
|
| Percent Change (as a percent) |
63.10%
|
|
| Innovative Medicine | Oncology | TALVEY |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 152
|
86
|
| Percent Change (as a percent) |
76.70%
|
|
| Innovative Medicine | Oncology | TALVEY | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 101
|
68
|
| Percent Change (as a percent) |
48.50%
|
|
| Innovative Medicine | Oncology | TALVEY | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 51
|
18
|
| Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 257
|
141
|
| Percent Change (as a percent) |
82.70%
|
|
| Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 175
|
113
|
| Percent Change (as a percent) |
55.10%
|
|
| Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 82
|
28
|
| Innovative Medicine | Oncology | ERLEADA |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 949
|
771
|
| Percent Change (as a percent) |
23.10%
|
|
| Innovative Medicine | Oncology | ERLEADA | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 342
|
292
|
| Percent Change (as a percent) |
17.30%
|
|
| Innovative Medicine | Oncology | ERLEADA | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 607
|
479
|
| Percent Change (as a percent) |
26.70%
|
|
| Innovative Medicine | Oncology | IMBRUVICA |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 660
|
709
|
| Percent Change (as a percent) |
(6.90%)
|
|
| Innovative Medicine | Oncology | IMBRUVICA | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 143
|
235
|
| Percent Change (as a percent) |
(39.10%)
|
|
| Innovative Medicine | Oncology | IMBRUVICA | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 517
|
474
|
| Percent Change (as a percent) |
9.10%
|
|
| Innovative Medicine | Oncology | Other Oncology |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 192
|
214
|
| Percent Change (as a percent) |
(10.60%)
|
|
| Innovative Medicine | Oncology | Other Oncology | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 85
|
54
|
| Percent Change (as a percent) |
58.80%
|
|
| Innovative Medicine | Oncology | Other Oncology | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 106
|
160
|
| Percent Change (as a percent) |
(33.90%)
|
|
| Innovative Medicine | Immunology |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 3,380
|
3,707
|
| Percent Change (as a percent) |
(8.80%)
|
|
| Innovative Medicine | Immunology | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,855
|
2,196
|
| Percent Change (as a percent) |
(15.50%)
|
|
| Innovative Medicine | Immunology | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,524
|
1,510
|
| Percent Change (as a percent) |
0.90%
|
|
| Innovative Medicine | Immunology | Tremfya |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,608
|
956
|
| Percent Change (as a percent) |
68.30%
|
|
| Innovative Medicine | Immunology | Tremfya | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,042
|
599
|
| Percent Change (as a percent) |
73.90%
|
|
| Innovative Medicine | Immunology | Tremfya | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 566
|
356
|
| Percent Change (as a percent) |
58.90%
|
|
| Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 647
|
659
|
| Percent Change (as a percent) |
(1.70%)
|
|
| Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 269
|
292
|
| Percent Change (as a percent) |
(7.80%)
|
|
| Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 378
|
366
|
| Percent Change (as a percent) |
3.00%
|
|
| Innovative Medicine | Immunology | Remicade |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 422
|
467
|
| Percent Change (as a percent) |
(9.50%)
|
|
| Innovative Medicine | Immunology | Remicade | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 269
|
314
|
| Percent Change (as a percent) |
(14.40%)
|
|
| Innovative Medicine | Immunology | Remicade | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 18
|
10
|
| Percent Change (as a percent) |
78.60%
|
|
| Innovative Medicine | Immunology | Remicade | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 136
|
143
|
| Percent Change (as a percent) |
(4.80%)
|
|
| Innovative Medicine | Immunology | STELARA |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 656
|
1,625
|
| Percent Change (as a percent) |
(59.70%)
|
|
| Innovative Medicine | Immunology | STELARA | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 220
|
981
|
| Percent Change (as a percent) |
(77.60%)
|
|
| Innovative Medicine | Immunology | STELARA | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 435
|
644
|
| Percent Change (as a percent) |
(32.40%)
|
|
| Innovative Medicine | Immunology | OTHER IMMUNOLOGY |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 46
|
1
|
| Innovative Medicine | Immunology | OTHER IMMUNOLOGY | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
38
|
1
|
| Innovative Medicine | Immunology | OTHER IMMUNOLOGY | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
9
|
0
|
| Innovative Medicine | Infectious Diseases |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 889
|
802
|
| Percent Change (as a percent) |
10.80%
|
|
| Innovative Medicine | Infectious Diseases | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 342
|
315
|
| Percent Change (as a percent) |
8.60%
|
|
| Innovative Medicine | Infectious Diseases | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 547
|
487
|
| Percent Change (as a percent) |
12.20%
|
|
| Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 409
|
358
|
| Percent Change (as a percent) |
14.10%
|
|
| Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 7
|
8
|
| Percent Change (as a percent) |
(13.10%)
|
|
| Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 402
|
350
|
| Percent Change (as a percent) |
14.80%
|
|
| Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 443
|
403
|
| Percent Change (as a percent) |
10.00%
|
|
| Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 334
|
305
|
| Percent Change (as a percent) |
9.50%
|
|
| Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 109
|
98
|
| Percent Change (as a percent) |
11.20%
|
|
| Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 37
|
41
|
| Percent Change (as a percent) |
(10.40%)
|
|
| Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1
|
2
|
| Percent Change (as a percent) |
(56.90%)
|
|
| Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 36
|
39
|
| Percent Change (as a percent) |
(8.30%)
|
|
| Innovative Medicine | Neuroscience |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 2,175
|
1,647
|
| Percent Change (as a percent) |
32.00%
|
|
| Innovative Medicine | Neuroscience | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,494
|
968
|
| Percent Change (as a percent) |
54.30%
|
|
| Innovative Medicine | Neuroscience | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 681
|
679
|
| Percent Change (as a percent) |
0.30%
|
|
| Innovative Medicine | Neuroscience | SPRAVATO |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 468
|
320
|
| Percent Change (as a percent) |
46.40%
|
|
| Innovative Medicine | Neuroscience | SPRAVATO | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 406
|
276
|
| Percent Change (as a percent) |
47.00%
|
|
| Innovative Medicine | Neuroscience | SPRAVATO | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 61
|
43
|
| Percent Change (as a percent) |
42.40%
|
|
| Innovative Medicine | Neuroscience | CAPLYTA |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 270
|
0
|
| Innovative Medicine | Neuroscience | CAPLYTA | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
270
|
0
|
| Innovative Medicine | Neuroscience | CAPLYTA | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 0
|
0
|
| Percent Change (as a percent) |
0.00%
|
|
| Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,038
|
903
|
| Percent Change (as a percent) |
15.00%
|
|
| Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 758
|
625
|
| Percent Change (as a percent) |
21.20%
|
|
| Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 280
|
277
|
| Percent Change (as a percent) |
1.10%
|
|
| Innovative Medicine | Neuroscience | CONCERTA/Methylphenidate |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 136
|
148
|
| Percent Change (as a percent) |
(8.00%)
|
|
| Innovative Medicine | Neuroscience | CONCERTA/Methylphenidate | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 22
|
38
|
| Percent Change (as a percent) |
(43.40%)
|
|
| Innovative Medicine | Neuroscience | CONCERTA/Methylphenidate | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 115
|
110
|
| Percent Change (as a percent) |
4.30%
|
|
| Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 262
|
277
|
| Percent Change (as a percent) |
(5.40%)
|
|
| Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 38
|
28
|
| Percent Change (as a percent) |
32.60%
|
|
| Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 224
|
248
|
| Percent Change (as a percent) |
(9.70%)
|
|
| Innovative Medicine | Pulmonary Hypertension |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,135
|
1,025
|
| Percent Change (as a percent) |
10.70%
|
|
| Innovative Medicine | Pulmonary Hypertension | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 831
|
744
|
| Percent Change (as a percent) |
11.70%
|
|
| Innovative Medicine | Pulmonary Hypertension | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 304
|
281
|
| Percent Change (as a percent) |
8.20%
|
|
| Innovative Medicine | Pulmonary Hypertension | UPTRAVI |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 483
|
451
|
| Percent Change (as a percent) |
7.10%
|
|
| Innovative Medicine | Pulmonary Hypertension | UPTRAVI | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 385
|
365
|
| Percent Change (as a percent) |
5.40%
|
|
| Innovative Medicine | Pulmonary Hypertension | UPTRAVI | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 98
|
86
|
| Percent Change (as a percent) |
14.30%
|
|
| Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 606
|
522
|
| Percent Change (as a percent) |
16.10%
|
|
| Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 433
|
363
|
| Percent Change (as a percent) |
19.30%
|
|
| Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 172
|
159
|
| Percent Change (as a percent) |
8.70%
|
|
| Innovative Medicine | Pulmonary Hypertension | Other |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 46
|
52
|
| Percent Change (as a percent) |
(12.10%)
|
|
| Innovative Medicine | Pulmonary Hypertension | Other | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 12
|
15
|
| Percent Change (as a percent) |
(21.10%)
|
|
| Innovative Medicine | Pulmonary Hypertension | Other | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 34
|
37
|
| Percent Change (as a percent) |
(8.30%)
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 876
|
1,013
|
| Percent Change (as a percent) |
(13.60%)
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 734
|
855
|
| Percent Change (as a percent) |
(14.20%)
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 142
|
158
|
| Percent Change (as a percent) |
(10.40%)
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | Other |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 233
|
323
|
| Percent Change (as a percent) |
(27.80%)
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | Other | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 91
|
165
|
| Percent Change (as a percent) |
(44.50%)
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | Other | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 142
|
158
|
| Percent Change (as a percent) |
(10.40%)
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 642
|
690
|
| Percent Change (as a percent) |
(7.00%)
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 642
|
690
|
| Percent Change (as a percent) |
(7.00%)
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 0
|
0
|
| Percent Change (as a percent) |
0.00%
|
|
| Innovative Medicine | Total PH, ID, CVM | Other |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 2,899
|
2,840
|
| Percent Change (as a percent) |
2.10%
|
|
| Innovative Medicine | Total PH, ID, CVM | Other | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,907
|
1,914
|
| Percent Change (as a percent) |
(0.40%)
|
|
| Innovative Medicine | Total PH, ID, CVM | Other | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 993
|
926
|
| Percent Change (as a percent) |
7.10%
|
|
| MEDTECH |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 8,636
|
8,020
|
| Percent Change (as a percent) |
7.70%
|
|
| MEDTECH | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 4,459
|
4,213
|
| Percent Change (as a percent) |
5.90%
|
|
| MEDTECH | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 4,177
|
3,807
|
| Percent Change (as a percent) |
9.70%
|
|
| MEDTECH | Cardiovascular |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 2,377
|
2,103
|
| Percent Change (as a percent) |
13.00%
|
|
| MEDTECH | Cardiovascular | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,399
|
1,261
|
| Percent Change (as a percent) |
10.90%
|
|
| MEDTECH | Cardiovascular | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 978
|
842
|
| Percent Change (as a percent) |
16.10%
|
|
| MEDTECH | ELECTROPHYSIOLOGY |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,489
|
1,323
|
| Percent Change (as a percent) |
12.60%
|
|
| MEDTECH | ELECTROPHYSIOLOGY | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 736
|
684
|
| Percent Change (as a percent) |
7.60%
|
|
| MEDTECH | ELECTROPHYSIOLOGY | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 753
|
638
|
| Percent Change (as a percent) |
18.00%
|
|
| MEDTECH | ABIOMED |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 488
|
420
|
| Percent Change (as a percent) |
16.30%
|
|
| MEDTECH | ABIOMED | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 389
|
339
|
| Percent Change (as a percent) |
14.50%
|
|
| MEDTECH | ABIOMED | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 100
|
81
|
| Percent Change (as a percent) |
23.50%
|
|
| MEDTECH | Shockwave |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 305
|
258
|
| Percent Change (as a percent) |
18.50%
|
|
| MEDTECH | Shockwave | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 242
|
206
|
| Percent Change (as a percent) |
17.80%
|
|
| MEDTECH | Shockwave | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 63
|
52
|
| Percent Change (as a percent) |
21.30%
|
|
| MEDTECH | Other Cardiovascular |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 94
|
103
|
| Percent Change (as a percent) |
(9.10%)
|
|
| MEDTECH | Other Cardiovascular | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 32
|
32
|
| Percent Change (as a percent) |
0.70%
|
|
| MEDTECH | Other Cardiovascular | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 62
|
72
|
| Percent Change (as a percent) |
(13.40%)
|
|
| MEDTECH | Orthopaedics |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 2,383
|
2,241
|
| Percent Change (as a percent) |
6.30%
|
|
| MEDTECH | Orthopaedics | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,435
|
1,384
|
| Percent Change (as a percent) |
3.70%
|
|
| MEDTECH | Orthopaedics | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 948
|
857
|
| Percent Change (as a percent) |
10.60%
|
|
| MEDTECH | Orthopaedics | HIPS |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 436
|
409
|
| Percent Change (as a percent) |
6.50%
|
|
| MEDTECH | Orthopaedics | HIPS | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 277
|
263
|
| Percent Change (as a percent) |
5.20%
|
|
| MEDTECH | Orthopaedics | HIPS | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 159
|
146
|
| Percent Change (as a percent) |
8.90%
|
|
| MEDTECH | Orthopaedics | KNEES |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 420
|
389
|
| Percent Change (as a percent) |
7.90%
|
|
| MEDTECH | Orthopaedics | KNEES | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 239
|
231
|
| Percent Change (as a percent) |
3.30%
|
|
| MEDTECH | Orthopaedics | KNEES | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 181
|
158
|
| Percent Change (as a percent) |
14.60%
|
|
| MEDTECH | Orthopaedics | TRAUMA |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 833
|
772
|
| Percent Change (as a percent) |
8.00%
|
|
| MEDTECH | Orthopaedics | TRAUMA | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 532
|
502
|
| Percent Change (as a percent) |
6.10%
|
|
| MEDTECH | Orthopaedics | TRAUMA | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 301
|
270
|
| Percent Change (as a percent) |
11.40%
|
|
| MEDTECH | Orthopaedics | SPINE & OTHER |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 694
|
671
|
| Percent Change (as a percent) |
3.50%
|
|
| MEDTECH | Orthopaedics | SPINE & OTHER | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 387
|
388
|
| Percent Change (as a percent) |
(0.10%)
|
|
| MEDTECH | Orthopaedics | SPINE & OTHER | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 307
|
283
|
| Percent Change (as a percent) |
8.40%
|
|
| MEDTECH | Surgery |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 2,511
|
2,396
|
| Percent Change (as a percent) |
4.80%
|
|
| MEDTECH | Surgery | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,046
|
1,002
|
| Percent Change (as a percent) |
4.40%
|
|
| MEDTECH | Surgery | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,465
|
1,394
|
| Percent Change (as a percent) |
5.10%
|
|
| MEDTECH | Surgery | ADVANCED |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,123
|
1,073
|
| Percent Change (as a percent) |
4.60%
|
|
| MEDTECH | Surgery | ADVANCED | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 477
|
457
|
| Percent Change (as a percent) |
4.20%
|
|
| MEDTECH | Surgery | ADVANCED | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 646
|
616
|
| Percent Change (as a percent) |
4.90%
|
|
| MEDTECH | Surgery | GENERAL |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,388
|
1,323
|
| Percent Change (as a percent) |
4.90%
|
|
| MEDTECH | Surgery | GENERAL | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 569
|
544
|
| Percent Change (as a percent) |
4.50%
|
|
| MEDTECH | Surgery | GENERAL | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 819
|
778
|
| Percent Change (as a percent) |
5.20%
|
|
| MEDTECH | Vision |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 1,365
|
1,279
|
| Percent Change (as a percent) |
6.70%
|
|
| MEDTECH | Vision | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 579
|
566
|
| Percent Change (as a percent) |
2.40%
|
|
| MEDTECH | Vision | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 785
|
713
|
| Percent Change (as a percent) |
10.10%
|
|
| MEDTECH | Vision | CONTACT LENSES / OTHER |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 969
|
919
|
| Percent Change (as a percent) |
5.50%
|
|
| MEDTECH | Vision | CONTACT LENSES / OTHER | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 468
|
452
|
| Percent Change (as a percent) |
3.70%
|
|
| MEDTECH | Vision | CONTACT LENSES / OTHER | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 501
|
467
|
| Percent Change (as a percent) |
7.20%
|
|
| MEDTECH | Vision | SURGICAL |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 396
|
361
|
| Percent Change (as a percent) |
9.70%
|
|
| MEDTECH | Vision | SURGICAL | U.S. |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 111
|
114
|
| Percent Change (as a percent) |
(2.90%)
|
|
| MEDTECH | Vision | SURGICAL | International |
|
|
| Sales by segment of business |
|
|
| Sales to customers |
$ 285
|
$ 246
|
| Percent Change (as a percent) |
15.60%
|
|